Published in Liver Transpl on October 01, 2011
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol (2015) 0.81
Progesterone increases apoptosis and inversely decreases autophagy in human hepatoma HA22T/VGH cells treated with epirubicin. ScientificWorldJournal (2014) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg (1993) 3.91
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26
Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg (1991) 3.12
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology (2007) 2.66
Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology (2008) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation (2008) 2.48
Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg (2002) 2.14
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst (2007) 2.11
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg (1995) 2.03
Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology (1993) 1.90
Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg (1998) 1.90
Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl (2004) 1.88
Liver transplantation for hepatocellular carcinoma. Semin Liver Dis (1999) 1.78
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol (2010) 1.77
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (2000) 1.33
Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl (2001) 1.31
Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl (2007) 1.27
Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl (2007) 1.27
Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg (2001) 1.21
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant (2009) 1.13
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol (2009) 1.07
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol (2010) 1.05
Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl (2002) 0.99
Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer (1994) 0.99
Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2007) 0.94
Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl (2004) 0.92
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology (2010) 0.91
Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant (2005) 0.90
Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl (2008) 0.87
Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol (2010) 0.86
A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int (2006) 0.85
[Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi (2005) 0.79
[Value of perioperative adjuvant therapy in liver transplantation for advanced hepatocellular carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao (2007) 0.79
Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol (2007) 0.79
[Clinical study of adjuvant individualized chemotherapy for hepatocellular carcinoma after liver transplantation]. Zhonghua Wai Ke Za Zhi (2004) 0.79
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol (2004) 2.29
Open letter to Xi Jinping, President of the People's Republic of China: China's fight against corruption in organ transplantation. Transplantation (2014) 2.11
Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol (2003) 1.69
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59
Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with MEN2A. Endocr J (2009) 1.54
Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation (2004) 1.49
Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2010) 1.49
Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. Transplantation (2002) 1.48
Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys (2011) 1.46
Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl (2003) 1.46
Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. Transplantation (2003) 1.45
Duct-to-duct biliary reconstruction in living donor liver transplantation utilizing right lobe graft. Ann Surg (2002) 1.37
Biliary reconstruction in right lobe living-donor liver transplantation: Comparison of different techniques in 321 recipients. Ann Surg (2006) 1.35
C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 1.33
Living donor liver transplantation for giant hepatic hemangioma with Kasabach-Merritt syndrome with a posterior segment graft. Liver Transpl (2002) 1.26
Surgery-related morbidity in living donors of right-lobe liver graft: lessons from the first 200 cases. Transplantation (2003) 1.09
Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay. J Clin Microbiol (2007) 1.08
Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection. World J Surg (2011) 1.01
Living-donor liver transplantation for hepatocellular carcinoma. Transplantation (2003) 1.00
Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch (2005) 1.00
Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health (2011) 0.98
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer (2011) 0.97
Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist (2010) 0.96
Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res (2010) 0.96
Liver transplantation for multiple liver metastases from solid pseudopapillary tumor of the pancreas. J Pediatr Surg (2007) 0.96
KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. J Mol Diagn (2013) 0.95
Small-for-size graft: not defined solely by being small for size. Liver Transpl (2010) 0.94
CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics (2004) 0.94
Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl (2013) 0.94
Background and clinical impact of tissue congestion in right-lobe living-donor liver grafts: a magnetic resonance imaging study. Transplantation (2003) 0.93
Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients. Endocr J (2013) 0.93
Factors influencing liver regeneration following living-donor liver transplantation of the right hepatic lobe. Transplantation (2003) 0.92
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther (2006) 0.92
Intrathecal trastuzumab: dose matters. Acta Oncol (2012) 0.91
Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation (2004) 0.90
A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. Am J Transplant (2002) 0.90
Upregulation of Bag-1 by ex vivo gene transfer protects rat livers from ischemia/reperfusion injury. Hum Gene Ther (2002) 0.90
Changing PET/CT manifestation of neurolymphomatosis. Eur J Nucl Med Mol Imaging (2006) 0.90
Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. BMC Cancer (2014) 0.89
Hilar cholangiocarcinoma. J Gastrointest Surg (2004) 0.89
Role of a novel oncogenic protein, gankyrin, in hepatocyte proliferation. J Gastroenterol (2003) 0.88
Living-related liver transplantation for Alagille syndrome. Transplantation (2003) 0.88
Fatal graft-versus-host disease after living donor liver transplantation: differential impact of donor-dominant one-way HLA matching. Liver Transpl (2006) 0.88
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother (2007) 0.87
Impact of non-congestive graft size in living donor liver transplantation: new indicator for additional vein reconstruction in right liver graft. Liver Transpl (2007) 0.86
Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer. Thyroid (2011) 0.85
Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr J (2009) 0.85
Characterization of erythrovirus B19 genomes isolated in liver tissues from patients with fulminant hepatitis and biliary atresia who underwent liver transplantation. Int J Med Sci (2007) 0.85
Surgical site infection in living-donor liver transplant recipients: a prospective study. Transplantation (2004) 0.84
[Case of acquired hepatocerebral degeneration with prominent improvement of parkinsonism and cognitive deficits after living-donor liver transplantation]. Rinsho Shinkeigaku (2012) 0.83
Right anterior sector drainage in right-lobe live-donor liver transplantation. Transplantation (2003) 0.82
Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet (2003) 0.82
The use of radial artery interpositional graft between recipient splenic artery and graft artery in living donor liver transplantation. Transpl Int (2006) 0.82
Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl (2013) 0.81
Two cases of central venous catheter-related thrombosis in living liver donors: how can the risk be minimized? Clin Transplant (2009) 0.81
Comparison of RBCs and FFP with whole blood during liver transplant surgery. Transfusion (2003) 0.81
Living-donor liver transplantation in the new decade: perspective from the twentieth to the twenty-first century. J Hepatobiliary Pancreat Surg (2002) 0.81
Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol (2010) 0.80
Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. J Infect Dis (2010) 0.80
De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis. Ann Hepatol (2009) 0.79
Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients. Vaccine (2011) 0.79
Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result. Surg Today (2006) 0.79
Living donor liver transplantation for congenital absence of the portal vein in a child with cardiac failure. J Pediatr Surg (2006) 0.79
Treatment of cancer pain with noninvasive brain stimulation. J Pain Symptom Manage (2007) 0.79
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer (2009) 0.79
Accuracy of stress myocardial perfusion imaging to diagnose coronary artery disease in end stage liver disease patients. Am J Cardiol (2013) 0.79
Use of the Model for End-Stage Liver Disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation. J Gastroenterol (2008) 0.78
Long-term results of surgery for papillary thyroid carcinoma with local recurrence. Surg Today (2012) 0.78
Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. Int J Cancer (2008) 0.78
Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation. J Neurol Neurosurg Psychiatry (2010) 0.78
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Oncology (2007) 0.77
Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. HPB (Oxford) (2014) 0.77
Subclinical central pontine myelinolysis following liver transplantation. Brain Dev (2002) 0.77
Long-term dynamics of hematological data and spleen volume in cirrhotic patients after liver transplantation-various dynamics depending on etiology. Springerplus (2013) 0.77
Liver transplantation without isoniazid prophylaxis for recipients with a history of tuberculosis. Clin Transplant (2007) 0.77
Biliary bacteria in living related liver transplant recipients: microbiology and rapid detection system using flow cytometry. Clin Chem Lab Med (2003) 0.77
Efficacy of anterior segment drainage reconstruction in right-lobe liver grafts from living donors. Transplantation (2004) 0.77
Intracellular signaling in the induction of apoptosis in a human breast cancer cell line by water extract of Mekabu. Int J Clin Oncol (2005) 0.76
Indirect immunohistochemical evaluation of graft fibrosis and interface hepatitis after pediatric liver transplantation. Pediatr Transplant (2009) 0.76
Long-term effects of liver transplantation on bone mineral density in children with end-stage liver disease: a 2-year prospective study. Liver Transpl (2003) 0.76
Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation. J Pharmacol Exp Ther (2008) 0.76
Pneumothorax ex-vacuo or "trapped lung" in the setting of hepatic hydrothorax. BMC Pulm Med (2012) 0.76
Effectiveness and safety of inactivated influenza vaccination in pediatric liver transplant recipients over three influenza seasons. Pediatr Transplant (2010) 0.76
Monosegmental living-donor liver transplantation for infantile hepatic hemangioendothelioma. J Pediatr Surg (2003) 0.76
Bruton's Tyrosine Kinase Inhibition Attenuates Liver Damage in a Mouse Warm Ischemia and Reperfusion Model. Transplantation (2016) 0.75
Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transplant (2013) 0.75
Innate Immune Regulations and Liver Ischemia-Reperfusion Injury. Transplantation (2016) 0.75
[Fever and neutropenia]. Praxis (Bern 1994) (2013) 0.75
Identification of Epstein-Barr virus-infected CD27+ memory B-cells in liver or stem cell transplant patients. J Gen Virol (2011) 0.75
Gray-scale ultrasonography shows serial changes of the congestive area after living donor liver transplantation using right lobe graft. Hepatogastroenterology (2010) 0.75
Donor screening algorithm for exclusion of thrombophilia during evaluation of living donor liver transplantation. Clin Transplant (2011) 0.75
Risk factors of recipient receiving living donor liver transplantation in the comprehensive era of indication and perioperative managements. Nagoya J Med Sci (2010) 0.75
Serial measurement of Doppler hepatic hemodynamic parameters for the diagnosis of acute rejection after live donor liver transplantation. Liver Transpl (2009) 0.75
Anti-hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virus-positive patients. Hepatol Res (2011) 0.75
Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. Drug Metab Pharmacokinet (2008) 0.75